And Then There Were None: Celltrion Signs AbbVie Licensing Deal for Its Adalimumab Biosimilar CT-P17
Celltrion and Teva Snag Second Biosimilar Approval of a Genentech Drug | BioSpace
Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International
Celltrion signs $160m drug license deal with Teva for North America - Nikkei Asia
Teva expects FDA preapproval inspection of troubled Celltrion plant this year | Fierce Pharma
Teva and Celltrion Launch Herzuma (biosimilar- trastuzumab) in the US
Celltrion presents Truxima's results of phase 3 clinical trials in US forum
Teva & Celltrion, Amgen & Allergan submit Herceptin biosimilars to FDA
Teva and Celltrion Launch Trastuzumab Biosimilar in U.S. - Big Molecule Watch
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | World Pharma Today
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion | Pharmafile
Celltrion/Teva Rituxan biosimilar edges closer to US approval -
Teva buys US rights to Celltrion biosimilars -
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Celltrion, Teva announce FDA approval of HERZUMA
Deal Watch: Teva and Celltrion Announce Biosimilar Commercial Partnership - Big Molecule Watch
Teva bolsters its biosimilar business through $160m Celltrion deal
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Teva, Celltrion Partner | Technology Networks
Biosimilars: Celltrion paves way for Herceptin copycats in 2018 - Pharmaceutical Technology
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
